Welcome to our dedicated page for Integer Hldgs news (Ticker: ITGR), a resource for investors and traders seeking the latest updates and insights on Integer Hldgs stock.
Integer Holdings Corporation (NYSE: ITGR), a global leader in medical device manufacturing, provides this centralized hub for investors and industry professionals to track its latest developments. Access official press releases, regulatory updates, and strategic announcements from the company powering innovation in cardiac rhythm management, neuromodulation, and vascular medical technologies.
This resource offers critical insights into ITGR's operations as a pure-play medical CDMO, including product launches, manufacturing expansions, and quality certifications. Key updates cover advancements in implantable device components, partnerships with healthcare OEMs, and progress in meeting stringent medical industry standards.
Regularly updated content includes earnings reports, R&D milestones, and supply chain developments relevant to the company's focus on high-reliability medical manufacturing. Visitors can monitor ITGR's strategic positioning in markets served through brands like Greatbatch Medical while staying informed about its transition from diversified holdings to specialized medtech solutions.
Bookmark this page for direct access to verified updates about Integer's manufacturing capabilities, regulatory compliance achievements, and technological innovations that impact global healthcare delivery. Check back frequently to stay informed about developments shaping the future of medical device outsourcing.
Integer Holdings Corporation (NYSE:ITGR) reported a strong performance in Q1 2023, with sales increasing 22% to $379 million and organic growth of 21%. GAAP net income rose by $2 million to $13 million, while non-GAAP adjusted net income grew by $3 million to $29 million. GAAP operating income surged 52% to $34 million, and adjusted operating income increased 28% to $50 million. Adjusted EBITDA also saw a 22% rise to $66 million. However, total debt increased by $77 million, reaching $1,002 million, resulting in a leverage ratio of 3.6 times adjusted EBITDA. The company anticipates organic sales growth of 7% to 9% for the full year 2023, with continued margin expansion expected.
Integer Holdings Corporation (NYSE:ITGR) will release its first quarter 2023 financial results on April 27, 2023, at 7 a.m. CT / 8 a.m. ET. Following the earnings release, a conference call will be held at 8 a.m. CT / 9 a.m. ET to discuss the results and any material forward-looking information. Investors can access the call via domestic or international dial-in numbers, with a conference ID of 9252310. Audio replay will be available for seven days. Integer is a leading medical device outsourcing manufacturer, providing innovative technologies across multiple markets.
Integer Holdings Corporation (NYSE:ITGR) will participate in a virtual fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023, at 10:30 AM ET. The chat will feature Joe Dziedzic, President and CEO, and Jason Garland, CFO. Interested investors can access the live and archived webcast via the company’s investor relations website. Integer is a leading medical device outsourcing manufacturer, serving various markets including cardiac and orthopedics.
Integer Holdings Corporation (NYSE:ITGR) reported a 19% sales growth in Q4 2022, reaching $372 million, with annual sales up 13% to $1.376 billion. Despite the growth, GAAP income decreased 15% to $17 million in Q4 and 30% to $65 million for the full year. Adjusted net income rose 12% to $37 million in Q4. The company expects 7% to 9% sales growth in 2023, driven by improving operational efficiencies and capacity investments. Debt increased to $925 million, linked to the Aran Biomedical acquisition. Integer remains optimistic about sustained above-market growth despite challenges in the supply chain.
Integer Holdings Corporation (NYSE: ITGR) announced the successful closing of its $500 million convertible senior notes offering, reducing its floating-rate debt. The offering was oversubscribed, increasing from $375 million to $500 million due to strong investor demand. The new 2.125% notes, due 2028, will decrease annual interest expenses by approximately $15 million, enhancing earnings immediately in 2023. The proceeds will repay existing debt, aligning the maturity of the notes with current obligations. The enhanced conversion structure aims to minimize future dilution, with a conversion price at a significant premium to the current stock price.
Integer Holdings Corporation (NYSE: ITGR) will exhibit at the MD&M West Exposition in Anaheim, California, from Feb. 7-9, 2023. At booth #1759, Integer will showcase its end-to-end medical device design, development, and manufacturing solutions, enhanced by the acquisitions of Aran Biomedical and Oscor. Key innovations include the new Gen 2 CFx Battery Technology, advanced electrophysiology solutions, and a comprehensive suite of neurovascular and structural heart capabilities. President Payman Khales emphasized the company’s focus on expanding its global footprint and capabilities to meet rising customer demand.
Integer Holdings Corporation (NYSE: ITGR) has announced the pricing of $435 million in 2.125% convertible senior notes due 2028, up from an initial size of $375 million. The offering, set to close on February 3, 2023, comes with an option for purchasers to acquire an additional $65 million. The net proceeds, estimated at $422.2 million, will primarily be used to pay off existing borrowings and expenses associated with capped call transactions valued at $30.5 million. The conversion price of $87.20 per share reflects a 32.5% premium over the January 31 closing price of $65.81. This move aims to reduce exposure to floating rate debt.
Integer Holdings Corporation (NYSE: ITGR) announced preliminary financial results for Q4 and full year 2022. Q4 sales are projected between $370 million and $372 million, an increase of 18% to 19% year-over-year, with organic growth of 12% to 13%. GAAP operating income is expected to rise by 25% to 29% to $36 to $37 million. For the full year, sales are projected at $1.374 to $1.376 billion, a 13% increase. However, GAAP operating income is anticipated to decrease by 11% to $120 to $121 million. The company will provide detailed 2023 guidance during the earnings call on February 16, 2023.
Integer Holdings Corporation (ITGR) has announced its intention to offer $375 million in convertible senior notes due February 15, 2028, with an option for purchasers to acquire an additional $56.25 million. Proceeds from this offering will be allocated to capped call transactions and the repayment of borrowings under the Company’s term B loan. This move aims to reduce the company’s exposure to floating-rate debt and stabilize cash interest expenses. The notes will be convertible under specified conditions and may lead to potential dilution of common stock.
Integer Holdings Corporation (NYSE: ITGR) will showcase its advanced capabilities in neuromodulation at the 26th North American Neuromodulation Society Annual Meeting in Las Vegas from Jan. 12-14, 2023. The company, a leader in medical device outsourcing, invites attendees to visit booth #525 to explore new implantable devices resulting from the Oscor acquisition in December 2021. Integer will also present its Xcellion Gen 3 Fast Charge Lithium Ion battery technology, offering best-in-class runtime with recharges in just 30 minutes, emphasizing innovation in active implantables.
FAQ
What is the current stock price of Integer Hldgs (ITGR)?
What is the market cap of Integer Hldgs (ITGR)?
